Interestingly, "Zhao" et al. revealed EGFR/VEGF inhibition therapy was transcendent to single EGFR inhibition, but not VEGF inhibition, for advanced NSCLC [25]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.